Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp136 | Female Reproduction | ECE2017

Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin improved beta cell function and prevented a conversion rate to MTG and DM2 in metformin intolerant PCOS with high metabolic risk

Janez Andrej , Ferjan Simona , Jensterle Mojca

Objective: Metformin is the first-line therapy for PCOS with high metabolic risk, yet a large proportion of patients cannot tolerate it due to associated gastrointestinal adverse events. The alternative pharmacological strategy when metformin cannot be tolerated is not well established in this population. Our aim was to evaluate whether sitagliptin (SITA) preserves metabolic profile in metformin (MET) intolerant PCOS with high metabolic risk.Design and m...

ea0056gp129 | Female Reproduction | ECE2018

Impaired GLP-1 response predicts prediabetes in obese PCOS with adverse metabolic phenotype independent of BMI

Jensterle Mojca , Ferjan Simona , Janez Andrej

Objective: Impaired glucose homeostasis in PCOS is closely linked to obesity, age and disease phenotype. The potential separate role of reduced GLP-1 response in the development of prediabetes in this population is unclear.Aim: To compare the GLP-1 response after OGTT in a cohort of obese PCOS with normal glucose tolerance (NGT) and prediabetes.Design/participants/methods: Case control study recruited 26 obese Caucasian women with ...

ea0090rc10.3 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2023

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: A 2-year observational study

Jensterle Mojca , Ferjan Simona , Goricar Katja , Janez Andrej

Background: Withdrawal of anti-obesity medication is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. In STEP 1 trial extension participants regained two-thirds of their prior weight loss during the 1-year off-treatment follow-up period after withdrawal of semaglutide 2.4 mg and discontinuation of active lifestyle intervention support. There are some studies implying that metformin might attenuat...

ea0081oc5.2 | Oral Communications 5: Diabetes, Obesity, Metabolism and Nutrition 2 | ECE2022

Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS

Jensterle Mojca , Ferjan Simona , Lezaic Luka , Socan Aljaz , Zaletel Katja , Janez Andrej

Background: GLP-1 agonism have the potential to affect gastric emptying (GE), yet the reports for subcutaneous semaglutide, currently the most effective GLP-1 RA approved for weight management, remain inconclusive. It has been demonstrated that semaglutide either had no effect on GE or it delayed GE only within the first hour, without late phase retention. Notably, those conclusions were made by an indirect method of estimation of GE through ingestion, absorption and determina...

ea0090oc1.2 | Oral Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2023

Semaglutide alters tongue transcriptome along with the improvement of taste perception and increased brain activation in response to sweet tasting solution in obese women with PCOS

Jensterle Mojca , Vovk Andrej , Kovac Jernej , Battelino Saba , Ferjan Simona , Hrast Barbara , Battelino Tadej , Janez Andrej

Background: Obese individuals may perceive the taste of caloric dense food as less intense, resulting in decreased activation of the reward system. Preclinical research provides some insights into the role of GLP-1 in the gustatory coding. The impact of GLP-1 receptor agonists on the tongue and taste perception remains largely unaddressed in clinical settings.Aim: to investigate the impact of semaglutide on the tongue transcriptome, taste perception and ...

ea0073aep163 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Semaglutide reduces fat accumulation in the tongue of obese women with polycystic ovary syndrome: A randomized, placebo-controlled prospective study

Jensterle Mojca , Ferjan Simona , Vovk Andrej , Battelino Tadej , Rizzo Manfredi , Janez Andrej

ObjectiveFat depot in the tongue that represents 25–30% of the total tongue mass is largely unaddressed. It correlates with body mass index. The response to weight reduction induced by different anti-obesity modalities may vary between body fat compartments. Semaglutide, a long acting GLP-1 receptor agonist (GLP-1 RA), has the potential to reduce body mass with at least 2 to 3 times greater weight reduction than other studied GLP-1 RAs. This is the ...